Samaly Souza Svigel1, Adicath Adeothy2,3, Augustin Kpemasse2, Ernest Houngbo2, Antoine Sianou2, Ramani Saliou4, Monica E Patton5,6, Fortune Dagnon6, Eric S Halsey5,7, Alexis Tchevoede2, Venkatachalam Udhayakumar5, Naomi W Lucchi5. 1. Malaria Branch, Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, GA, USA. ynp4@cdc.gov. 2. National Malaria Control Programme, Ministry of Health, Cotonou, Benin. 3. John Snow, Inc. (JSI) , MA, Boston, USA. 4. Accelerating the Reduction of Malaria Morbidity and Mortality Project (ARM3), Medical Care Development International, Cotonou, Benin. 5. Malaria Branch, Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, GA, USA. 6. U.S. President's Malaria Initiative, USAID, Cotonou, Benin. 7. U.S. President's Malaria Initiative, GA, Atlanta, USA.
Abstract
BACKGROUND: In 2004, in response to high levels of treatment failure associated with sulfadoxine-pyrimethamine (SP) resistance, Benin changed its first-line malaria treatment from SP to artemisinin-based combination therapy for treatment of uncomplicated Plasmodium falciparum malaria. Resistance to SP is conferred by accumulation of single nucleotide polymorphisms (SNPs) in P. falciparum genes involved in folate metabolism, dihydrofolate reductase (Pfdhfr) and dihydropteroate synthase (Pfdhps), targeted by pyrimethamine and sulfadoxine, respectively. Because SP is still used for intermittent preventive treatment in pregnant women (IPTp) and seasonal malaria chemoprevention (SMCP) in Benin, the prevalence of Pfdhfr and Pfdhps SNPs in P. falciparum isolates collected in 2017 were investigated. METHODS: This study was carried out in two sites where the transmission of P. falciparum malaria is hyper-endemic: Klouékanmey and Djougou. Blood samples were collected from 178 febrile children 6-59 months old with confirmed uncomplicated P. falciparum malaria and were genotyped for SNPs associated with SP resistance. RESULTS: The Pfdhfr triple mutant IRN (N51I, C59R, and S108N) was the most prevalent (84.6%) haplotype and was commonly found with the Pfdhps single mutant A437G (50.5%) or with the Pfdhps double mutant S436A and A437G (33.7%). The quintuple mutant, Pfdhfr IRN/Pfdhps GE (A437G and K540E), was rarely observed (0.8%). The A581G and A613S mutant alleles were found in 2.6 and 3.9% of isolates, respectively. Six isolates (3.9%) were shown to harbour a mutation at codon I431V, recently identified in West African parasites. CONCLUSIONS: This study showed that Pfdhfr triple IRN mutants are near fixation in this population and that the highly sulfadoxine-resistant Pfdhps alleles are not widespread in Benin. These data support the continued use of SP for chemoprevention in these study sites, which should be complemented by periodic nationwide molecular surveillance to detect emergence of resistant genotypes.
BACKGROUND: In 2004, in response to high levels of treatment failure associated with sulfadoxine-pyrimethamine (SP) resistance, Benin changed its first-line malaria treatment from SP to artemisinin-based combination therapy for treatment of uncomplicated Plasmodium falciparummalaria. Resistance to SP is conferred by accumulation of single nucleotide polymorphisms (SNPs) in P. falciparum genes involved in folate metabolism, dihydrofolate reductase (Pfdhfr) and dihydropteroate synthase (Pfdhps), targeted by pyrimethamine and sulfadoxine, respectively. Because SP is still used for intermittent preventive treatment in pregnant women (IPTp) and seasonal malaria chemoprevention (SMCP) in Benin, the prevalence of Pfdhfr and Pfdhps SNPs in P. falciparum isolates collected in 2017 were investigated. METHODS: This study was carried out in two sites where the transmission of P. falciparum malaria is hyper-endemic: Klouékanmey and Djougou. Blood samples were collected from 178 febrile children 6-59 months old with confirmed uncomplicated P. falciparum malaria and were genotyped for SNPs associated with SP resistance. RESULTS: The Pfdhfr triple mutant IRN (N51I, C59R, and S108N) was the most prevalent (84.6%) haplotype and was commonly found with the Pfdhps single mutant A437G (50.5%) or with the Pfdhps double mutant S436A and A437G (33.7%). The quintuple mutant, Pfdhfr IRN/Pfdhps GE (A437G and K540E), was rarely observed (0.8%). The A581G and A613S mutant alleles were found in 2.6 and 3.9% of isolates, respectively. Six isolates (3.9%) were shown to harbour a mutation at codon I431V, recently identified in West African parasites. CONCLUSIONS: This study showed that Pfdhfr triple IRN mutants are near fixation in this population and that the highly sulfadoxine-resistant Pfdhps alleles are not widespread in Benin. These data support the continued use of SP for chemoprevention in these study sites, which should be complemented by periodic nationwide molecular surveillance to detect emergence of resistant genotypes.
Entities:
Keywords:
Drug resistance; Intermittent Preventive Treatment in Pregnant; Malaria; Pfdhfr; Pfdhps; Pregnant women; Seasonal Malaria Chemoprevention; Sulfadoxine Pyrimethamine
Authors: Michael Alifrangis; John P Lusingu; Bruno Mmbando; Michael B Dalgaard; Lasse S Vestergaard; Deus Ishengoma; Insaf F Khalil; Thor G Theander; Martha M Lemnge; Ib C Bygbjerg Journal: Am J Trop Med Hyg Date: 2009-04 Impact factor: 2.345
Authors: Lena Hommerich; Christa von Oertzen; George Bedu-Addo; Ville Holmberg; Patrick A Acquah; Teunis A Eggelte; Ulrich Bienzle; Frank P Mockenhaupt Journal: Malar J Date: 2007-11-08 Impact factor: 2.979
Authors: Richard J Pearce; Hirva Pota; Marie-Solange B Evehe; El-Hadj Bâ; Ghyslain Mombo-Ngoma; Allen L Malisa; Rosalynn Ord; Walter Inojosa; Alexandre Matondo; Diadier A Diallo; Wilfred Mbacham; Ingrid V van den Broek; Todd D Swarthout; Asefaw Getachew; Seyoum Dejene; Martin P Grobusch; Fanta Njie; Samuel Dunyo; Margaret Kweku; Seth Owusu-Agyei; Daniel Chandramohan; Maryline Bonnet; Jean-Paul Guthmann; Sian Clarke; Karen I Barnes; Elizabeth Streat; Stark T Katokele; Petrina Uusiku; Chris O Agboghoroma; Olufunmilayo Y Elegba; Badara Cissé; Ishraga E A-Elbasit; Hayder A Giha; S Patrick Kachur; Caroline Lynch; John B Rwakimari; Pascalina Chanda; Moonga Hawela; Brian Sharp; Inbarani Naidoo; Cally Roper Journal: PLoS Med Date: 2009-04-14 Impact factor: 11.069
Authors: Jenny Hill; Kassoum Kayentao; Mahamoudou Touré; Sory Diarwara; Jane Bruce; James Smedley; Ogobara K Doumbo; Feiko O ter Kuile; Jayne Webster Journal: PLoS One Date: 2014-03-20 Impact factor: 3.240